Pharmacological HIF2α inhibition improves VHL disease–associated phenotypes in zebrafish model

Ana M. Metelo, Haley R. Noonan, Xiang Li, Youngnam N. Jin, Rania Baker, Lee Kamentsky, Yiyun Zhang, Ellen van Rooijen, Jordan T. Shin, Anne E. Carpenter, Jing-Ruey Joanna Yeh, Randall T. Peterson, Othon IliopoulosJournal of Clinical Investigation 2015 · DOI

Abstract

Patients with a germline mutation in von Hippel-Lindau (VHL) develop renal cell cancers and hypervascular tumors of the brain, adrenal glands, and pancreas as well as erythrocytosis. These phenotypes are driven by aberrant expression of HIF2α, which induces expression of genes involved in cell proliferation, angiogenesis, and red blood cell production. Currently, there are no effective treatments available for VHL disease. Here, using an animal model of VHL, we report a marked improvement of VHL-associated phenotypes following treatment with HIF2α inhibitors. Inactivation of vhl in zebrafish led to constitutive activation of HIF2α orthologs and modeled several aspects of the human disease, including erythrocytosis, pathologic angiogenesis in the brain and retina, and aberrant kidney and liver proliferation. Treatment of vhl(-/-) mutant embryos with HIF2α-specific inhibitors downregulated Hif target gene expression in a dose-dependent manner, improved abnormal hematopoiesis, and substantially suppressed erythrocytosis and angiogenic sprouting. Moreover, pharmacologic inhibition of HIF2α reversed the compromised cardiac contractility of vhl(-/-) embryos and partially rescued early lethality. This study demonstrates that small-molecule targeting of HIF2α improves VHL-related phenotypes in a vertebrate animal model and supports further exploration of this strategy for treating VHL disease.

Introduction: The Challenge of VHL Disease

Von Hippel-Lindau (VHL) disease is a hereditary condition characterized by a "constellation" of hypervascular tumors in the brain, retina, kidneys, and pancreas, alongside erythrocytosis—a dangerous overproduction of red blood cells. The root cause is a mutation in the VHL gene. Normally, the VHL protein marks the transcription factor HIF2α for destruction. Without functional VHL, HIF2α accumulates, triggering uncontrolled angiogenesis and red blood cell production by mimicking a state of chronic hypoxia.

Currently, medical treatments are lacking, leaving patients to face repeated, invasive surgeries. A major hurdle in drug development has been specifically targeting HIF2α without interfering with its relative, HIF1α, which can have beneficial or tumor-suppressive roles depending on the context.

Methods and Mechanism of Action

Researchers utilized the zebrafish (Danio rerio) as a primary model due to its highly conserved signaling pathways for blood vessel formation and erythropoiesis. They employed vhl−/− mutant zebrafish, which naturally develop symptoms mirroring human VHL patients.

To address the disease, the team tested "Compound 76" (C76), a small molecule that inhibits HIF2α translation. Unlike traditional drugs that block protein activity, C76 prevents the protein's production by promoting the binding of Iron Regulatory Protein 1 (IRP1) to a specific Iron Responsive Element (IRE) on the HIF2α mRNA.

Compound 76 inhibits HIF2α translation by stabilizing the IRP1-IRE complex on the mRNA.

The study combined high-resolution confocal imaging of transgenic vascular reporter lines (Tg(fli1:GFP)) with machine learning tools like Ilastik to objectively quantify vascular architecture and hemoglobin staining (O-dianisidine), removing human bias from the analysis.

Key Insights: Specificity and the "Aha" Moment

A critical discovery was the confirmation that zebrafish HIF2α orthologs (epas1a and epas1b) contain the IRE "lock" in their mRNA, while HIF1α orthologs do not. This structural difference allows Compound 76 to selectively shut down oncogenic HIF2α while leaving HIF1α untouched.

Compound 76 selectively targets the 5'UTR of HIF2α orthologs (epas1a/b) but not HIF1α orthologs.

Further knockout experiments revealed that epas1a is the dominant driver of the VHL phenotype in zebrafish, identifying it as the primary therapeutic target. By hitting this "master switch" at the translational level, the drug effectively suppresses a broad range of downstream disease triggers.

Key Results

  • Gene Suppression: C76 dose-dependently downregulated key disease-driving genes, including epo (erythropoiesis) and vegfab (angiogenesis).
  • Phenotype Reversal: Treatment normalized hemoglobin levels and "trimmed" chaotic vascular networks in the brain and tail of mutant embryos.
  • Cardiac Rescue: One of the most significant findings was the improvement of cardiac contractility. vhl−/− embryos typically suffer from heart failure; C76 improved ventricular fractional shortening from 0.54 to a near-normal 0.61 (Wild Type is 0.62).
  • Survival: Pharmacological inhibition significantly extended the lifespan of the larvae, delaying the early lethality characteristic of the vhl mutation.

Discussion and Future Directions

While these results provide a powerful proof-of-concept, the compounds used are non-optimized hits from a screen. Future work must focus on medicinal chemistry to improve potency and drug-like properties for human administration. Additionally, while the rescue was observed in early larval stages, VHL is a lifelong condition; the long-term safety and pharmacokinetics of suppressing HIF2α translation in humans require further investigation. Nevertheless, this study validates the zebrafish as a robust tool for drug discovery and positions HIF2α translation inhibitors as a promising frontier for VHL therapy.

Summary updated

Abstract

Patients with a germline mutation in von Hippel-Lindau (VHL) develop renal cell cancers and hypervascular tumors of the brain, adrenal glands, and pancreas as well as erythrocytosis. These phenotypes are driven by aberrant expression of HIF2α, which induces expression of genes involved in cell proliferation, angiogenesis, and red blood cell production. Currently, there are no effective treatments available for VHL disease. Here, using an animal model of VHL, we report a marked improvement of VHL-associated phenotypes following treatment with HIF2α inhibitors. Inactivation of vhl in zebrafish led to constitutive activation of HIF2α orthologs and modeled several aspects of the human disease, including erythrocytosis, pathologic angiogenesis in the brain and retina, and aberrant kidney and liver proliferation. Treatment of vhl(-/-) mutant embryos with HIF2α-specific inhibitors downregulated Hif target gene expression in a dose-dependent manner, improved abnormal hematopoiesis, and substantially suppressed erythrocytosis and angiogenic sprouting. Moreover, pharmacologic inhibition of HIF2α reversed the compromised cardiac contractility of vhl(-/-) embryos and partially rescued early lethality. This study demonstrates that small-molecule targeting of HIF2α improves VHL-related phenotypes in a vertebrate animal model and supports further exploration of this strategy for treating VHL disease.
BibTeX
@article{metelo2015pharmacological,
  author = {Ana M. Metelo and Haley R. Noonan and Xiang Li and Youngnam N. Jin and Rania Baker and Lee Kamentsky and Yiyun Zhang and Ellen van Rooijen and Jordan T. Shin and Anne E. Carpenter and Jing-Ruey Joanna Yeh and Randall T. Peterson and Othon Iliopoulos},
  title = {{Pharmacological HIF2α inhibition improves VHL disease–associated phenotypes in zebrafish model}},
  journal = {Journal of Clinical Investigation},
  year = {2015},
  doi = {10.1172/jci73665},
}
Figure